Top

Published in:

Open Access 01-03-2012 | Research Paper

Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model

Authors: Hidenori Ozaki, Hideki Matsuzaki, Hidenobu Ando, Hiroyuki Kaji, Hayao Nakanishi, Yuzuru Ikehara, Hisashi Narimatsu

Published in: Clinical & Experimental Metastasis | Issue 3/2012

Abstract

ST6GalNAcI is a sialyltransferase responsible for the synthesis of sialyl Tn (sTn) antigen which is expressed in a variety of adenocarcinomas including gastric cancer especially in advanced cases, but the roles of ST6GalNAcI and sTn in cancer progression are largely unknown. We generated sTn-expressing human gastric cancer cells by ectopic expression of ST6GalNAcI to evaluate metastatic ability of these cells and prognostic effect of ST6GalNAcI and sTn in a mouse model, and identified sTn carrier proteins to gain insight into the function of ST6GalNAcI and sTn in gastric cancer progression. A green fluorescent protein-tagged human gastric cancer cell line was transfected with ST6GalNAcI to produce sTn-expressing cells, which were transplanted into nude mice. STn-positive gastric cancer cells showed higher intraperitoneal metastatic ability in comparison with sTn-negative control, resulting in shortened survival time of the mice, which was mitigated by anti-sTn antibody administration. Then, sTn-carrying proteins were immunoprecipitated from culture supernatants and lysates of these cells, and identified MUC1 and CD44 as major sTn carriers. It was confirmed that MUC1 carries sTn also in human advanced gastric cancer tissues. Identification of sTn carrier proteins will help understand mechanisms of metastatic phenotype acquisition of gastric cancer cells by ST6GalNAcI and sTn.

Werther JL, Rivera-MacMurray S, Bruckner H et al (1994) Mucin-associated sialosyl-Tn antigen expression in gastric cancer correlates with an adverse outcome. Br J Cancer 69(3):613–616PubMedCrossRef

Werther JL, Tatematsu M, Klein R et al (1996) Sialosyl-Tn antigen as a marker of gastric cancer progression: an international study. Int J Cancer 69(3):193–199PubMedCrossRef

Ma XC, Terata N, Kodama M et al (1993) Expression of sialyl-Tn antigen is correlated with survival time of patients with gastric carcinomas. Eur J Cancer 29A(13):1820–1823PubMedCrossRef

Itzkowitz SH, Bloom EJ, Kokal WA et al (1990) Sialosyl-Tn. A novel mucin antigen associated with prognosis in colorectal cancer patients. Cancer 66(9):1960–1966PubMedCrossRef

Guadagni F, Roselli M, Cosimelli M et al (1996) Correlation between tumor-associated glycoprotein 72 mucin levels in tumor and serum of colorectal patients as measured by the quantitative CA 72–4 immunoassay. Cancer Res 56(22):5293–5298PubMed

Ghazizadeh M, Ogawa H, Sasaki Y et al (1997) Mucin carbohydrate antigens (T, Tn, and sialyl-Tn) in human ovarian carcinomas: relationships with histopathology and prognosis. Hum Pathol 28(8):960–966PubMedCrossRef

Kobayashi H, Terao T, Kawashima Y (1992) Serum sialyl Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol 10(1):95–101PubMed

Cho SH, Sahin A, Hortobagyi GN et al (1994) Sialyl-Tn antigen expression occurs early during human mammary carcinogenesis and is associated with high nuclear grade and aneuploidy. Cancer Res 54(24):6302–6305PubMed

Schuessler MH, Pintado S, Welt S et al (1991) Blood group and blood-group-related antigens in normal pancreas and pancreas cancer: enhanced expression of precursor type 1, Tn and sialyl-Tn in pancreas cancer. Int J Cancer 47(2):180–187PubMedCrossRef

10.

Dabelsteen E (1996) Cell surface carbohydrates as prognostic markers in human carcinomas. J Pathol 179(4):358–369PubMedCrossRef

11.

Kakeji Y, Maehara Y, Morita M et al (1995) Correlation between sialyl Tn antigen and lymphatic metastasis in patients with Borrmann type IV gastric carcinoma. Br J Cancer 71(1):191–195PubMedCrossRef

12.

Nakagoe T, Sawai T, Tsuji T et al (2002) Predictive factors for preoperative serum levels of sialyl Lewis(x), sialyl Lewis(a) and sialyl Tn antigens in gastric cancer patients. Anticancer Res 22(1A):451–458PubMed

13.

Koga S, Kaibara N, Iitsuka Y et al (1984) Prognostic significance of intraperitoneal free cancer cells in gastric cancer patients. J Cancer Res Clin Oncol 108(2):236–238PubMedCrossRef

14.

Kodera Y, Nakanishi H, Yamamura Y et al (1998) Prognostic value and clinical implications of disseminated cancer cells in the peritoneal cavity detected by reverse transcriptase-polymerase chain reaction and cytology. Int J Cancer 79(4):429–433PubMedCrossRef

15.

Nakanishi H, Kodera Y, Yamamura Y et al (2000) Rapid quantitative detection of carcinoembryonic antigen-expressing free tumor cells in the peritoneal cavity of gastric-cancer patients with real-time RT-PCR on the lightcycler. Int J Cancer 89(5):411–417PubMedCrossRef

16.

Ikehara Y, Kojima N, Kurosawa N et al (1999) Cloning and expression of a human gene encoding an N-acetylgalactosamine-α2, 6-sialyltransferase (ST6GalNAc I): a candidate for synthesis of cancer-associated sialyl-Tn antigens. Glycobiology 9(11):1213–1224PubMedCrossRef

17.

Marcos NT, Pinho S, Grandela C et al (2004) Role of the human ST6GalNAc-I and ST6GalNAc-II in the synthesis of the cancer-associated sialyl-Tn antigen. Cancer Res 64(19):7050–7057PubMedCrossRef

18.

Julien S, Krzewinski-Recchi MA, Harduin-Lepers A et al (2001) Expression of sialyl-Tn antigen in breast cancer cells transfected with the human CMP-Neu5Ac: GalNAc α2, 6-sialyltransferase (ST6GalNAc I) cDNA. Glycoconj J 18(11–12):883–893PubMedCrossRef

19.

Brockhausen I, Yang J, Lehotay M et al (2001) Pathways of mucin O-glycosylation in normal and malignant rat colonic epithelial cells reveal a mechanism for cancer-associated Sialyl-Tn antigen expression. Biol Chem 382(2):219–232PubMedCrossRef

20.

Clément M, Rocher J, Loirand G et al (2004) Expression of sialyl-Tn epitopes on β1 integrin alters epithelial cell phenotype, proliferation and haptotaxis. J Cell Sci 117(Pt21):5059–5069PubMedCrossRef

21.

Pinho S, Marcos NT, Ferreira B et al (2007) Biological significance of cancer-associated sialy-Tn antigen: modulation of malignant phenotype in gastric carcinoma cells. Cancer Lett 249(2):157–170PubMedCrossRef

22.

Julien S, Adriaenssens E, Ottenberg K et al (2006) ST6GalNAc I expression in MDA-MB-231 breast cancer cells greatly modifies their O-glycosylation pattern and enhances their tumorigenicity. Glycobiology 16(1):54–64PubMedCrossRef

23.

Nakanishi H, Mochizuki Y, Kodera Y et al (2003) Chemosensitivity of peritoneal micrometastases as evaluated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Cancer Sci 94(1):112–118PubMedCrossRef

24.

Yokoyama H, Nakanishi H, Kodera Y et al (2006) Biological significance of isolated tumor cells and micrometastasis in lymph nodes evaluated using a green fluorescent protein-tagged human gastric cancer cell line. Clin Cancer Res 12(2):361–368PubMedCrossRef

25.

Colcher D, Hand PH, Nuti M et al (1981) A spectrum of monoclonal antibodies reactive with human mammry tumor cells. Proc Natl Acad Sci USA 78(5):3199–3203PubMedCrossRef

26.

Kjeldsen T, Clausen H, Hirohashi S et al (1988) Preparation and characterization of monoclonal antibodies directed to the tumor-associated O-linked sialosyl-2–6 α-N-acetylgalactosaminyl (sialosyl-Tn) epitope. Cancer Res 48(8):2214–2220PubMed

27.

Zhang S, Walberg LA, Ogata S et al (1995) Immune sera and monoclonal antibodies define two configurations for the sialyl Tn tumor antigen. Cancer Res 55(15):3364–3368PubMed

28.

Denda-Nagai K, Irimura T (2000) MUC1 in carcinoma-host interactions. Glycoconj J 17(7–9):649–658PubMedCrossRef

29.

Nakamori S, Ota DM, Cleary KR et al (1994) MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology 106(2):353–361PubMed

30.

Walsh MD, Hohn BG, Thong W et al (1994) Mucin expression by transitional cell carcinomas of the bladder. Br J Urol 73(3):256–262PubMedCrossRef

31.

Schroeder JA, Masri AA, Adriance MC et al (2004) MUC1 overexpression results in mammary gland tumorigenesis and prolonged alveolar differentiation. Oncogene 23(34):5739–5747PubMedCrossRef

32.

Li Y, Liu D, Chen D et al (2003) Human DF3/MUC1 carcinoma-associated protein functions as an oncogene. Oncogene 22(38):6107–6110PubMedCrossRef

33.

Satoh S, Hinoda Y, Hayashi T et al (2000) Enhancement of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an anti-adhesion molecule. Int J Cancer 88(4):507–518PubMedCrossRef

34.

Wesseling J, van der Valk SW, Hilkens J (1996) A mechanism for inhibition of E-cadherin-mediated cell–cell adhesion by the membrane–associated mucin episialin/MUC1. Mol Biol Cell 7(4):565–577PubMed

35.

Ligtenberg MJ, Buijs F, Vos HL et al (1992) Suppression of cellular aggregation by high levels of episialin. Cancer Res 52(8):2318–2324PubMed

36.

Lloyd KO, Burchell J, Kudryashov V et al (1996) Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. J Biol Chem 271(52):33325–33334PubMedCrossRef

37.

Burdick MD, Harris A, Reid CJ et al (1997) Oligosaccharides expressed on MUC1 produced by pancreatic and colon tumor cell lines. J Biol Chem 272(39):24198–24202PubMedCrossRef

38.

Kinarsky L, Suryanarayanan G, Prakash O et al (2003) Conformational studies on the MUC1 tandem repeat glycopeptides: implication for the enzymatic O-glycosylation of the mucin protein core. Glycobiology 13(12):929–939PubMedCrossRef

39.

Dziadek S, Griesinger C, Kunz H et al (2006) Synthesis and structural model of an α(2, 6)-sialyl-T glycosylated MUC1 eicosapeptide under physiological conditions. Chem Eur J 12(19):4981–4993PubMedCrossRef

40.

Marhaba R, Zöller M (2004) CD44 in cancer progression: adhesion, migration and growth regulation. J Mol Histol 35(3):211–231PubMedCrossRef

41.

Günthert U, Hofmann M, Rudy W et al (1991) A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 65(1):13–24PubMedCrossRef

42.

Seiter S, Arch R, Reber S et al (1993) Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med 177(2):443–455PubMedCrossRef

43.

Bretscher A, Edwards K, Fehon RG (2002) ERM proteins and merlin: integrators at the cell cortex. Natl Rev Mol Cell Biol 3(8):586–599CrossRef

44.

Tsukita S, Oishi K, Sato N et al (1994) ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons. J Cell Biol 126(2):391–401PubMedCrossRef

45.

Yonemura S, Hirao M, Doi Y et al (1998) Ezrin/radixin/moesin (ERM) proteins bind to a positively charged amino acid cluster in the juxta-membrane cytoplasmic domain of CD44, CD43, and ICAM-2. J Cell Biol 140(4):885–895PubMedCrossRef

46.

Labarrière N, Piau JP, Otry C et al (1994) H blood group antigen carried by CD44 V modulates tumorigenicity of rat colon carcinoma cells. Cancer Res 54(23):6275–6281PubMed

47.

Goupille C, Hallouin F, Meflah K et al (1997) Increase of rat colon carcinoma cells tumorigenicity by α(1–2) fucosyltransferase gene transfection. Glycobiology 7(2):221–229PubMedCrossRef

Title: Enhancement of metastatic ability by ectopic expression of ST6GalNAcI on a gastric cancer cell line in a mouse model
Authors: Hidenori Ozaki
Hideki Matsuzaki
Hidenobu Ando
Hiroyuki Kaji
Hayao Nakanishi
Yuzuru Ikehara
Hisashi Narimatsu
Publication date: 01-03-2012
Publisher: Springer Netherlands
Published in: Clinical & Experimental Metastasis / Issue 3/2012
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI: https://doi.org/10.1007/s10585-011-9445-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Palliative radiation therapy for pulmonary metastases from hepatocellular carcinoma

Erlotinib prevents experimental metastases of human small cell lung cancer cells with no epidermal growth factor receptor expression

Dormant but migratory tumour cells in desmoplastic stroma of invasive ductal carcinomas

Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation

Regulation of HGF-mediated cell proliferation and invasion through NF-κB, JunB, and MMP-9 cascades in stomach cancer cells

A novel mouse CD133 binding-peptide screened by phage display inhibits cancer cell motility in vitro

Keynote webinar | Spotlight on antibody–drug conjugates in cancer